Clinical Research Directory
Browse clinical research sites, groups, and studies.
Growth Hormone for the Treatment of Gastroparesis
Sponsor: Mayo Clinic
Summary
The purpose of this study is to determine whether treatment with Growth Hormone results in symptomatic improvement in patients with gastroparesis.
Official title: Low-dose Growth Hormone for the Treatment of Gastroparesis
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2024-10-22
Completion Date
2027-12
Last Updated
2026-04-16
Healthy Volunteers
No
Conditions
Interventions
Growth Hormone
Subjects will receive somapacitan-beco (Sogroya®) administered as a subcutaneous injection once weekly for 12 weeks. All participants will receive a fixed dose of 1.5 mg weekly, regardless of sex.
Locations (2)
Mayo Clinic
Phoenix, Arizona, United States
Mayo Clinic in Arizona
Scottsdale, Arizona, United States